Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

April 03, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group ... "We are pleased with the progress across our Alzheimer’s portfolio as we move ahead with a Phase III trontinemab ...

Roche’s Genentech unit has bought California biotech ... Jecure has a preclinical portfolio of NLRP-3 class drugs used to treat inflammatory and autoimmune disorders such as NASH, liver fibrosis ...

About Genentech in neuroscience Neuroscience is a major focus of research and development at Genentech and Roche. Our goal is to pursue groundbreaking science to develop new treatments that help ...

(KRON) — Biotech firm Genentech is laying off nearly 100 employees at its South San Francisco headquarters, according to a WARN notice from the California Employment Development Department (EDD).

But biotechnology leader Genentech, in part through its Advancing Inclusive Research® initiative, is striving to change that. Alongside industry stakeholders, the organization is testing new ...

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. Highlights included presentations from ...

Since its founding in San Francisco in 1976, biotechnology pioneer Genentech has helped revolutionize the way doctors treat some of the world’s most complex health challenges, including the ...

About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the ...